Taken together these data indicate that a combinative score grouping functional tests and skin biomarkers analysis constitute a reliable and robust measure of CMT1A gene therapy outcome in CMT1A rats. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.